Skip to main content
Erschienen in: Current Rheumatology Reports 6/2013

01.06.2013 | INFECTIONS AND ARTHRITIS (K WINTHROP, SECTION EDITOR)

Vaccination and Inflammatory Arthritis: Overview of Current Vaccines and Recommended Uses in Rheumatology

verfasst von: Claudia Müller-Ladner, Ulf Müller-Ladner

Erschienen in: Current Rheumatology Reports | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Patients with autoimmune inflammatory rheumatic diseases are prone to infectious complications during the course of their disease. The underlying disease with an impaired immune system and additional different immunosuppressive medication render patients more susceptible to infections, some of which are potentially preventable with vaccination. Since it is not clear how strongly the underlying and medication-induced immunosuppression interferes with vaccination, a lot of questions remain about its indications, efficacy and safety . Due to these unresolved questions, in 2011, EULAR published general guidelines about vaccination in patients with autoimmune rheumatic diseases. These guidelines provide a basis for patient care and are also the basis of the following review article. With more available and earlier used immunosuppressive medications, a lot of questions still remain about optimal use of vaccines, the role of different medication combinations on efficacy and safety of vaccinations especially of the actual prevention of disease, the role of age, gender, disease activity and duration, and optimal revaccination schedules in this patient group. Actual studies elute the role of different medication combinations on efficacy and safety mainly addressing influenza and pneumococcal vaccination. In addition, interesting new data on basic immunological processes during TNF-α-blockade open up questions for further research.
Literatur
1.
Zurück zum Zitat Glück T, Müller-Ladner U. Vaccination in Patients with Chronic Rheumatic or Autoimmune Diseases. Clin Infect Dis. 2008;46:1459–65.PubMedCrossRef Glück T, Müller-Ladner U. Vaccination in Patients with Chronic Rheumatic or Autoimmune Diseases. Clin Infect Dis. 2008;46:1459–65.PubMedCrossRef
2.
Zurück zum Zitat •• van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414–22. Provides state-of-the-art clinical guidelines for vaccination of patients with rheumatic diseases.PubMedCrossRef •• van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414–22. Provides state-of-the-art clinical guidelines for vaccination of patients with rheumatic diseases.PubMedCrossRef
3.
Zurück zum Zitat •• Heijstek MW, de Bruin LM O, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70:1704–12. Provides the current knowledge for vaccination of pediatric patients with rheumatic diseases.PubMedCrossRef •• Heijstek MW, de Bruin LM O, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70:1704–12. Provides the current knowledge for vaccination of pediatric patients with rheumatic diseases.PubMedCrossRef
4.
Zurück zum Zitat McCarthy EM, de Barra E, Bergin C, et al. Influenza and pneumococcal vaccination and varicella status in inflammatory arthritis patients. Ir Med J. 2011;104:208–11.PubMed McCarthy EM, de Barra E, Bergin C, et al. Influenza and pneumococcal vaccination and varicella status in inflammatory arthritis patients. Ir Med J. 2011;104:208–11.PubMed
5.
Zurück zum Zitat Lanternier F, Henegar C, Mouthon L, et al. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann Rheum Dis. 2008;67:1047–51.PubMedCrossRef Lanternier F, Henegar C, Mouthon L, et al. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann Rheum Dis. 2008;67:1047–51.PubMedCrossRef
6.
Zurück zum Zitat McCarthy EM, Azeez MA, Fitzpatrick FM, et al. Knowledge, attitudes, and clinical practice of rheumatologists in vaccination of the at-risk rheumatology patient population. J Clin Rheumatol. 2012;18:234–41.CrossRef McCarthy EM, Azeez MA, Fitzpatrick FM, et al. Knowledge, attitudes, and clinical practice of rheumatologists in vaccination of the at-risk rheumatology patient population. J Clin Rheumatol. 2012;18:234–41.CrossRef
7.
Zurück zum Zitat Feuchtenberger M, Kleinert S, Schwab S, et al. Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int. 2012;32:1533–9.PubMedCrossRef Feuchtenberger M, Kleinert S, Schwab S, et al. Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int. 2012;32:1533–9.PubMedCrossRef
8.
Zurück zum Zitat Desai SP, Lu B, Szent-Gyorgyi LE, et al. Increasing pneumococcal vaccination for immunosuppressed patients: A cluster quality improvement trial. Arthritis Rheum. 2013;65:39–47.PubMedCrossRef Desai SP, Lu B, Szent-Gyorgyi LE, et al. Increasing pneumococcal vaccination for immunosuppressed patients: A cluster quality improvement trial. Arthritis Rheum. 2013;65:39–47.PubMedCrossRef
9.
Zurück zum Zitat Mori S, Ueki Y, Hirakata N, et al. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012;71:2006–10.PubMedCrossRef Mori S, Ueki Y, Hirakata N, et al. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012;71:2006–10.PubMedCrossRef
10.
Zurück zum Zitat Adler S. Krivine a, Weix J et al. Protective effect of A/H1N1 vaccination in immune-mediated disease-a prospectively controlled vaccination study. Rheumatology. 2012;51:695–700.PubMedCrossRef Adler S. Krivine a, Weix J et al. Protective effect of A/H1N1 vaccination in immune-mediated disease-a prospectively controlled vaccination study. Rheumatology. 2012;51:695–700.PubMedCrossRef
11.
Zurück zum Zitat Kapetanovic MC, Roseman C, Jönsson G, et al. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011;63:3723–32.PubMedCrossRef Kapetanovic MC, Roseman C, Jönsson G, et al. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011;63:3723–32.PubMedCrossRef
12.
Zurück zum Zitat Kapetanovic MC, Roseman C, Jönsson G, et al. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin Rheumatol. 2011;30:1555–61.PubMedCrossRef Kapetanovic MC, Roseman C, Jönsson G, et al. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin Rheumatol. 2011;30:1555–61.PubMedCrossRef
13.
Zurück zum Zitat Bingham III CO, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62:64–74.PubMedCrossRef Bingham III CO, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62:64–74.PubMedCrossRef
14.
Zurück zum Zitat Kapetanovic MC, Saxne T, Truedsson L, et al. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different anti-rheumatic drugs. Arthritis Res Ther. 2013;15:R1.CrossRef Kapetanovic MC, Saxne T, Truedsson L, et al. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different anti-rheumatic drugs. Arthritis Res Ther. 2013;15:R1.CrossRef
15.
Zurück zum Zitat Heijstek MW, van Gageldonk PGM, Berbers GAM, et al. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis. 2012;71:948–54.PubMedCrossRef Heijstek MW, van Gageldonk PGM, Berbers GAM, et al. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis. 2012;71:948–54.PubMedCrossRef
16.
Zurück zum Zitat Milanovic M, Stojanovic L, Djokovic A, et al. Influenza vaccination in autoimmune rheumatic disease patients. Tohoku J Exp Med. 2013;229:29–34.PubMedCrossRef Milanovic M, Stojanovic L, Djokovic A, et al. Influenza vaccination in autoimmune rheumatic disease patients. Tohoku J Exp Med. 2013;229:29–34.PubMedCrossRef
17.
Zurück zum Zitat Franca ILA, Ribeiro ACM, Aikawa NE, et al. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology. 2012;51:2091–8.PubMedCrossRef Franca ILA, Ribeiro ACM, Aikawa NE, et al. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology. 2012;51:2091–8.PubMedCrossRef
18.
Zurück zum Zitat Mori S, Ueki Y, Akeda Y et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis, epub. Mori S, Ueki Y, Akeda Y et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis, epub.
19.
Zurück zum Zitat Visvanathan S, Keenan GF, Baker DG, et al. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol. 2007;34:952–7.PubMed Visvanathan S, Keenan GF, Baker DG, et al. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol. 2007;34:952–7.PubMed
20.
Zurück zum Zitat Lyrido LD, Grassi MF, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013;33:335–40.CrossRef Lyrido LD, Grassi MF, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013;33:335–40.CrossRef
21.
Zurück zum Zitat Tam LS, Chan PK, Ho SC, et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus – a prospective cohort study. J Rheumatol. 2010;37:333–40.CrossRef Tam LS, Chan PK, Ho SC, et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus – a prospective cohort study. J Rheumatol. 2010;37:333–40.CrossRef
22.
Zurück zum Zitat Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2012;19:1485–91.CrossRef Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2012;19:1485–91.CrossRef
23.
Zurück zum Zitat Dreyer L, Faurschou M, Mogensen M, et al. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long term followup study in a Danish cohort. Arthritis Rheum. 2011;63:3032–7.PubMedCrossRef Dreyer L, Faurschou M, Mogensen M, et al. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long term followup study in a Danish cohort. Arthritis Rheum. 2011;63:3032–7.PubMedCrossRef
24.
Zurück zum Zitat Santana IU, Gomes Ado N, Lyrio LD, et al. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol. 2011;30:665–72.PubMedCrossRef Santana IU, Gomes Ado N, Lyrio LD, et al. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol. 2011;30:665–72.PubMedCrossRef
25.
Zurück zum Zitat • Mok CC, Ho LY, Fong LS et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case–control study. Ann Rheum Dis 2012, epub. Vaccination study providing novel data on HPV vaccination in the relevant patient group. • Mok CC, Ho LY, Fong LS et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case–control study. Ann Rheum Dis 2012, epub. Vaccination study providing novel data on HPV vaccination in the relevant patient group.
26.
Zurück zum Zitat Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus. 2012;21:158–61.PubMedCrossRef Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus. 2012;21:158–61.PubMedCrossRef
27.
Zurück zum Zitat Centers for Disease Control and Prevention. Notes from the field: Severe varicella in an immunocompromised child exposed to an unvaccinated sibling with varicella – Minnesota, 2011. MMWR Morb Mortal Wkly Rep 2012;61:541. Centers for Disease Control and Prevention. Notes from the field: Severe varicella in an immunocompromised child exposed to an unvaccinated sibling with varicella – Minnesota, 2011. MMWR Morb Mortal Wkly Rep 2012;61:541.
28.
Zurück zum Zitat Borte S, Liebert UG, Borte M, et al. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology. 2009;48:144–8.PubMedCrossRef Borte S, Liebert UG, Borte M, et al. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology. 2009;48:144–8.PubMedCrossRef
29.
Zurück zum Zitat Pileggi GS, De Souza CBS, Ferriani VPL. Safety and Immunogenicity of Varicella Vaccine in Patients With Juvenile Rheumatic Diseases Receiving Methotrexate and Corticosteroids. Arthritis Care Res. 2012;62:1034–9.CrossRef Pileggi GS, De Souza CBS, Ferriani VPL. Safety and Immunogenicity of Varicella Vaccine in Patients With Juvenile Rheumatic Diseases Receiving Methotrexate and Corticosteroids. Arthritis Care Res. 2012;62:1034–9.CrossRef
30.
Zurück zum Zitat Heijstek MW, Pileggi GC. Zonneveld-Huijssoon et al. Safety of measled, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66:1384–7.PubMedCrossRef Heijstek MW, Pileggi GC. Zonneveld-Huijssoon et al. Safety of measled, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66:1384–7.PubMedCrossRef
31.
Zurück zum Zitat Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61:623–5.PubMedCrossRef Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61:623–5.PubMedCrossRef
32.
Zurück zum Zitat • Franco Salinas G, De Rycke L, Barendregt B et al. Anti-TNF treatment blocks induction of T-cell-dependent humoral responses. Ann Rheum Dis, epub. Interesting study regarding role of TNF blockade in B-cell activation. • Franco Salinas G, De Rycke L, Barendregt B et al. Anti-TNF treatment blocks induction of T-cell-dependent humoral responses. Ann Rheum Dis, epub. Interesting study regarding role of TNF blockade in B-cell activation.
Metadaten
Titel
Vaccination and Inflammatory Arthritis: Overview of Current Vaccines and Recommended Uses in Rheumatology
verfasst von
Claudia Müller-Ladner
Ulf Müller-Ladner
Publikationsdatum
01.06.2013
Verlag
Current Science Inc.
Erschienen in
Current Rheumatology Reports / Ausgabe 6/2013
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-013-0330-6

Weitere Artikel der Ausgabe 6/2013

Current Rheumatology Reports 6/2013 Zur Ausgabe

SYSTEMIC LUPUS ERYTHEMATOSUS (M PETRI, SECTION EDITOR)

Top 10 Things to Know About Lupus Activity Measures

INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTION EDITOR)

Autoantibodies in Polymyositis and Dermatomyositis

INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTION EDITOR)

The Role of Resistin in Inflammatory Myopathies

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Use of New Oral Anticoagulants in Antiphospholipid Syndrome

INFECTIONS AND ARTHRITIS (K WINTHROP, SECTION EDITOR)

Clinical Management of Septic Arthritis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.